Infection or bleeding after transrectal prostate biopsy remains a concern of both patients and urologists. We explored the risk of association of certain co-morbidities with both complications.
Patients and Methods:
Using the Taiwan National Health Insurance Research Database, we identified patients undergoing prostate biopsy from 2000 to 2013. We used logistic multivariable regression to search for associations between post-biopsy hospitalization and the two co-morbidities within a year after biopsy.
Results:
Among 3,601 prostate biopsies, 100 infections (3.77%) and 52 (1.44%) bleeding-related emergency room visits and hospitalizations were recorded within 30 days after biopsy. The group having the biopsy as an inpatient exhibited older age (p < 0.0001) and a higher percentage of having diabetes mellitus (p = 0.015) than patients without either complication. The logistic multivariable regression analysis showed that urinary retention, freedom from diabetes, and performance as an outpatient procedure were independent risk factors for infection-related hospitalization (odds ratios 1.81, 1.96, and 1.72; p values 0.031, 0.037, and 0.010, respectively).
Conclusion:
Patients with a recent history of urinary retention have a higher probability of infection-related hospitalization after prostate biopsy.
Get full access to this article
View all access options for this article.
References
1.
SiegelRL, MillerKD, JemalA. Cancer statistics, 2017. CA: Cancer J Clinic, 2017; 67:7–30.
2.
WiltTJ, JonesKM, BarryMJ, et al.Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med, 2017; 377:132–142.
3.
Bill-AxelsonA, HolmbergL, GarmoH, et al.Radical prostatectomy or watchful waiting in early prostate cancer. N Eng J Med, 2014; 370:932–942.
4.
MottetN, BellmuntJ, BollaM, et al.EAU-ESTRO-SIOG Guidelines on Prostate Cancer 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol, 2017; 71:618–629.
5.
RoehrbornCG, AndrioleGL, WilsonTH, et al.Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol, 2011; 59:244–249.
6.
MaiZ, YanW, ZhouY, et al.Transperineal template-guided prostate biopsy: 10 years of experience. BJU Int, 2016; 117:424–429.
7.
WuTT, HuangJK. Annual changes in the clinical features of prostatic adenocarcinoma in Taiwan. BJU Int, 2001; 87:57–60.
8.
LanSK, TsaiYS, LinYH, et al.Diagnostic performance of a random versus lesion-directed biopsy of the prostate from transrectal ultrasound: Results of a 5-year consecutive clinical study in 1 institution in South Taiwan. J Ultrasound Med, 2007; 26:11–17.
9.
WeiTC, LinTP, ChangYH, et al.Transrectal ultrasound-guided prostate biopsy in Taiwan: A nationwide database study. J Chinese Med Assoc, 2015; 78:662–665.
10.
DesmondPM, ClarkJ, ThompsonIM, et al.Morbidity with contemporary prostate biopsy. J Urol, 1993; 150:1425–1426.
11.
LoebS, van den HeuvelS, ZhuX, et al.Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol, 2012; 61:1110–1114.
12.
BurdenHP, RanasingheW, PersadR. Antibiotics for transrectal ultrasonography-guided prostate biopsy: Are we practising evidence-based medicine?. BJU Int, 2008; 101:1202–1204.
13.
TalR, LivnePM, LaskDM, et al.Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol, 2003; 169:1762–1765.
14.
HuangYC, HoDR, WuCF, al. Modified bowel preparation to reduce infection after prostate biopsy. Chang Gung Med J, 2006; 29:395–400.
15.
CareyJM, KormanHJ. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications?. J Urol, 2001; 166:82–85.
16.
LindertKA, KabalinJN, TerrisMK. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J Urol, 2000; 164:76–80.
17.
SummersSJ, PatelDP, HamiltonBD, et al.An antimicrobial prophylaxis protocol using rectal swab cultures for transrectal prostate biopsy. World J Urol, 2015; 33:2001–2007.
18.
SimsirA, KismaliE, MammadovR, et al.Is it possible to predict sepsis, the most serious complication in prostate biopsy?. Urol Int, 2010; 84:395–399.
19.
LeeSH, ChenSM, HoCR, et al.Risk factors associated with transrectal ultrasound guided prostate needle biopsy in patients with prostate cancer. Chang Gung Med J, 2009; 32:623–627.
20.
GaylisF, NasseriR, FinkL, et al.Prostate biopsy complications: A dual analysis. Urology, 2016; 93:135–140.
21.
NamRK, SaskinR, LeeY, et al.Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol, 2010; 183:963–968.
22.
PinkhasovGI, LinYK, PalmerolaR, et al.Complications following prostate needle biopsy requiring hospital admission or emergency department visits: Experience from 1000 consecutive cases. BJU Int, 2012; 110:369–374.
23.
ZaytounOM, AnilT, MoussaAS, et al.Morbidity of prostate biopsy after simplified versus complex preparation protocols: Assessment of risk factors. Urology, 2011; 77:910–914.
24.
RuddickF, SandersP, BicknellSG, et al.Sepsis rates after ultrasound-guided prostate biopsy using a bowel preparation protocol in a community hospital. J Ultrasound Med, 2011; 30:213–216.
25.
MosharafaAA, TorkyMH, El SaidWM, et al.Rising incidence of acute prostatitis following prostate biopsy: Fluoroquinolone resistance and exposure is a significant risk factor. Urology, 2011; 78:511–514.
26.
LangeD, ZappavignaC, HamidizadehR, et al.Bacterial sepsis after prostate biopsy: A new perspective. Urology, 2009; 74:1200–1205.
27.
LindstedtS, LindstromU, LjunggrenE, et al.Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors. Eur Urol, 2006; 50:832–837.
28.
ZaytounOM, VargoEH, RajanR, et al.Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: Implications for prophylaxis and treatment. Urology, 2011; 77:1035–1041.
29.
WilliamsonDA, FreemanJT, PorterS, et al.Clinical and molecular correlates of virulence in Escherichia coli causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. J Antimicrob Chemother, 2013; 68:2898–2906.
30.
RagnarsdottirB, LutayN, Gronberg-HernandezJ, et al.Genetics of innate immunity and UTI susceptibility. Nat Rev Urol, 2011; 8:449–468.
31.
BrewsterDH, FischbacherCM, NolanJ, et al.Risk of hospitalization and death following prostate biopsy in Scotland. Public Health, 2017; 142:102–110.
32.
TsaiYS, ChenCH, JouYC, et al.Febrile infection in post-prostate biopsy: Results of a ten-year single-institution study in South Taiwan. Surg Infect, 2014; 15:24–28.
33.
CarignanA, RoussyJF, LapointeV, et al.Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: Time to reassess antimicrobial prophylaxis?. Eur Urol, 2012; 62:453–459.
34.
GaneswaranD, SweeneyC, YousifF, et al.Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol, 2014; 32:309–315.
35.
PepeP, AragonaF. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology, 2013; 81:1142–1146.
